News
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
30 Mar 24
Biotech, Cannabis, News, Psychedelics
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
20 Mar 24
Biotech, Cannabis, Psychedelics
Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment
14 Mar 24
Biotech, News, Legal, General
Cybin Announces End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
14 Mar 24
Government, News, Regulations
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
13 Mar 24
Biotech, Cannabis, Psychedelics, Financing, Legal
HC Wainwright & Co. Maintains Buy on Cybin, Maintains $5 Price Target
13 Mar 24
News, Price Target, Analyst Ratings
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
4 Mar 24
Cannabis, Psychedelics, Financing, FDA, Legal, Management, Global
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
16 Feb 24
Biotech, Cannabis, News, Penny Stocks, Psychedelics, FDA, Opinion, Markets, Trading Ideas, General
HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $5 Price Target
15 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
15 Feb 24
Cannabis, Psychedelics, Financing, Legal, Management, Global
'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
12 Feb 24
Biotech, News, FDA, General
Cybin Reveals Grant Of Two Additional Patents In Japan In Support Of Its DMT Program
7 Feb 24
News
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
27 Jan 24
Cannabis, Psychedelics, Financing, Legal, Management, Global, Top Stories, Markets
FDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxiety
23 Jan 24
Biotech, Cannabis, News, Psychedelics, Markets
Press releases
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
16 Apr 24
Press Releases
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 Apr 24
Press Releases
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
18 Mar 24
Press Releases
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
15 Mar 24
Press Releases
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO
15 Mar 24
News, Press Releases
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
14 Mar 24
Press Releases
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
13 Mar 24
Press Releases
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
12 Mar 24
Press Releases
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
27 Feb 24
Press Releases
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
14 Feb 24
Press Releases
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
7 Feb 24
Press Releases
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
24 Jan 24
Small Cap, Opinion, Press Releases
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
23 Jan 24
Press Releases